520 related articles for article (PubMed ID: 35455941)
1.
Smith L; Schapira AHV
Cells; 2022 Apr; 11(8):. PubMed ID: 35455941
[TBL] [Abstract][Full Text] [Related]
2. The role of glucocerebrosidase in Parkinson disease pathogenesis.
Gegg ME; Schapira AHV
FEBS J; 2018 Oct; 285(19):3591-3603. PubMed ID: 29385658
[TBL] [Abstract][Full Text] [Related]
3. Glucocerebrosidase and Parkinson disease: Recent advances.
Schapira AH
Mol Cell Neurosci; 2015 May; 66(Pt A):37-42. PubMed ID: 25802027
[TBL] [Abstract][Full Text] [Related]
4. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
5. Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments.
Gegg ME; Menozzi E; Schapira AHV
Neurobiol Dis; 2022 May; 166():105663. PubMed ID: 35183702
[TBL] [Abstract][Full Text] [Related]
6. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
[TBL] [Abstract][Full Text] [Related]
7. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
Menozzi E; Toffoli M; Schapira AHV
Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432
[TBL] [Abstract][Full Text] [Related]
8. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.
Behl T; Kaur G; Fratila O; Buhas C; Judea-Pusta CT; Negrut N; Bustea C; Bungau S
Transl Neurodegener; 2021 Jan; 10(1):4. PubMed ID: 33446243
[TBL] [Abstract][Full Text] [Related]
9. Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways.
Vieira SRL; Schapira AHV
Free Radic Biol Med; 2021 Nov; 175():42-55. PubMed ID: 34450264
[TBL] [Abstract][Full Text] [Related]
10. The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines.
Smith LJ; Bolsinger MM; Chau KY; Gegg ME; Schapira AHV
Hum Mol Genet; 2023 Feb; 32(5):773-789. PubMed ID: 36130205
[TBL] [Abstract][Full Text] [Related]
11. Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons.
Gegg ME; Verona G; Schapira AHV
Hum Mol Genet; 2020 Jun; 29(10):1716-1728. PubMed ID: 32391886
[TBL] [Abstract][Full Text] [Related]
12. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease.
Magalhaes J; Gegg ME; Migdalska-Richards A; Doherty MK; Whitfield PD; Schapira AH
Hum Mol Genet; 2016 Aug; 25(16):3432-3445. PubMed ID: 27378698
[TBL] [Abstract][Full Text] [Related]
13. [GBA mutations and Parkinson's disease].
Wang DX; Xie JX; Song N
Sheng Li Xue Bao; 2018 Jun; 70(3):294-300. PubMed ID: 29926071
[TBL] [Abstract][Full Text] [Related]
14. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.
Sanchez-Martinez A; Beavan M; Gegg ME; Chau KY; Whitworth AJ; Schapira AH
Sci Rep; 2016 Aug; 6():31380. PubMed ID: 27539639
[TBL] [Abstract][Full Text] [Related]
15. A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration.
Polissidis A; Koronaiou E; Nikolopoulou G; Viel C; Nikatou M; Bogiongko M; Sardi SP; Xilouri M; Vekrellis K; Stefanis L
Neurobiol Dis; 2022 Feb; 163():105612. PubMed ID: 34995756
[TBL] [Abstract][Full Text] [Related]
16. Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease.
Menozzi E; Schapira AHV
CNS Drugs; 2020 Sep; 34(9):915-923. PubMed ID: 32607746
[TBL] [Abstract][Full Text] [Related]
17. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
[TBL] [Abstract][Full Text] [Related]
18. Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications.
Balestrino R; Schapira AHV
Neuroscientist; 2018 Oct; 24(5):540-559. PubMed ID: 29400127
[TBL] [Abstract][Full Text] [Related]
19. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains.
Gegg ME; Burke D; Heales SJ; Cooper JM; Hardy J; Wood NW; Schapira AH
Ann Neurol; 2012 Sep; 72(3):455-63. PubMed ID: 23034917
[TBL] [Abstract][Full Text] [Related]
20. Glucocerebrosidase mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease.
Kurzawa-Akanbi M; Hanson PS; Blain PG; Lett DJ; McKeith IG; Chinnery PF; Morris CM
J Neurochem; 2012 Oct; 123(2):298-309. PubMed ID: 22803570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
